These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28341014)

  • 21. Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative.
    Solans L; Debrie AS; Coutte L; Locht C
    Vaccine; 2021 May; 39(21):2843-2849. PubMed ID: 33896662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acellular pertussis vaccines and pertussis resurgence: revise or replace?
    Ausiello CM; Cassone A
    mBio; 2014 Jun; 5(3):e01339-14. PubMed ID: 24917600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route.
    Li R; Lim A; Alonso S
    Bioeng Bugs; 2011; 2(6):315-9. PubMed ID: 22067832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whooping cough, twenty years from acellular vaccines introduction.
    Greco D; Esposito S; Tozzi A; Pandolfi E; Icardi G; Giammanco A
    Ann Ig; 2015; 27(2):415-31. PubMed ID: 26051141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a potential for novel, nasal pertussis vaccines?
    Locht C
    Expert Rev Vaccines; 2021 Apr; 20(4):415-423. PubMed ID: 33667341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.
    Kavanagh H; Noone C; Cahill E; English K; Locht C; Mahon BP
    Clin Exp Allergy; 2010 Jun; 40(6):933-41. PubMed ID: 20184606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changing from whole-cell to acellular pertussis vaccines would trade superior tolerability for inferior protection.
    Herzog C
    Expert Rev Vaccines; 2015; 14(8):1065-72. PubMed ID: 26098640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pertussis vaccines and the challenge of inducing durable immunity.
    Warfel JM; Edwards KM
    Curr Opin Immunol; 2015 Aug; 35():48-54. PubMed ID: 26091979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.
    Li R; Cheng C; Chong SZ; Lim AR; Goh YF; Locht C; Kemeny DM; Angeli V; Wong WS; Alonso S
    Allergy; 2012 Oct; 67(10):1250-8. PubMed ID: 22909095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity.
    Allen AC; Mills KH
    Expert Rev Vaccines; 2014 Oct; 13(10):1253-64. PubMed ID: 25017925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization against pertussis in adolescents and adults.
    Esposito S; Principi N;
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S89-S95. PubMed ID: 27130670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting future trends in the burden of pertussis in the 21st century: implications for infant pertussis and the success of maternal immunization.
    van den Biggelaar AH; Poolman JT
    Expert Rev Vaccines; 2016; 15(1):69-80. PubMed ID: 26559122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice.
    Mielcarek N; Debrie AS; Mahieux S; Locht C
    Clin Vaccine Immunol; 2010 Mar; 17(3):317-24. PubMed ID: 20107007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.
    Dubois V; Locht C
    Front Immunol; 2021; 12():701285. PubMed ID: 34211481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough.
    Mielcarek N; Debrie AS; Raze D; Bertout J; Rouanet C; Younes AB; Creusy C; Engle J; Goldman WE; Locht C
    PLoS Pathog; 2006 Jul; 2(7):e65. PubMed ID: 16839199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Licensed pertussis vaccines in the United States. History and current state.
    Klein NP
    Hum Vaccin Immunother; 2014; 10(9):2684-90. PubMed ID: 25483496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
    Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
    Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.
    Skerry CM; Mahon BP
    Clin Vaccine Immunol; 2011 Feb; 18(2):187-93. PubMed ID: 21147936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pertussis vaccine for adolescents and adults].
    Perret P C
    Rev Chilena Infectol; 2006 Sep; 23(3):257-60. PubMed ID: 16896501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.